Zimmer Biomet Holdings (XSWX:ZBH) Interest Expense : CHF-181 Mil (TTM As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Zimmer Biomet Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Zimmer Biomet Holdings's interest expense for the three months ended in Dec. 2023 was CHF -43 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-181 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Zimmer Biomet Holdings's Operating Income for the three months ended in Dec. 2023 was CHF 364 Mil. Zimmer Biomet Holdings's Interest Expense for the three months ended in Dec. 2023 was CHF -43 Mil. Zimmer Biomet Holdings's Interest Coverage for the quarter that ended in Dec. 2023 was 8.37. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Zimmer Biomet Holdings Interest Expense Historical Data

The historical data trend for Zimmer Biomet Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zimmer Biomet Holdings Interest Expense Chart

Zimmer Biomet Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-222.95

-188.43

-191.94

-153.53

-174.00

Zimmer Biomet Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-39.69	-44.61	-46.46	-45.97	-43.50

Zimmer Biomet Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-181 Mil.

Zimmer Biomet Holdings (XSWX:ZBH) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Zimmer Biomet Holdings's Interest Expense for the three months ended in Dec. 2023 was CHF-43 Mil. Its Operating Income for the three months ended in Dec. 2023 was CHF364 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was CHF4,335 Mil.

Zimmer Biomet Holdings's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	363.908	/	-43.499
	=	8.37

The higher the ratio, the stronger the company's financial strength is.

Zimmer Biomet Holdings (XSWX:ZBH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (XSWX:ZBH) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

ZBH:USA ZIM:Germany ZBH:Austria

Address

345 East Main Street, Warsaw, IN, USA, 46580

Website

https://www.zimmerbiomet.com

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.